Document:

halb_ex105.htm

EXHIBIT 10.5
  
 INDUSTRY SPONSORED RESEARCH AGREEMENT
 FIXED PRICE
  
 ASU Reference No. FP00026198
 Sponsor Reference No.
  
 This Sponsored Research Agreement (“Agreement”) is made and entered into by and between:
  
 The Arizona Board of Regents for and on behalf of Arizona State University (“ASU”), an institution of higher learning established by the laws of the State of Arizona, having a place of business at 660 S. Mill Ave., Tempe, AZ 85281, and Halberd Corporation, a publicly traded company, having a place of business at P.O. Box 25, Jackson Center, PA 16133 (“Sponsor”).
  
 Sponsor desires to fund research to be performed by ASU, as described in the scope of work attached hereto and incorporated herein as Exhibit A (the “Project”), and ASU desires to conduct such research, the Project contemplated by this Agreement is of mutual interest to Sponsor and ASU and furthers the educational, scholarship and research objectives of ASU as a nonprofit, tax-exempt, educational institution, and may benefit both Sponsor and ASU through the creation or discovery of new inventions.
  
 Therefore, in reliance on the commitments and obligations set forth herein, and with the intention of being legally bound hereby, the parties agree as follows:
  
 Effective Date. This Agreement will be effective as of the date of the last signature below.
  
 Scope of Work. ASU will use all reasonable efforts to perform the services and deliver any reports or other items specified in Exhibit A.
  
 Key Personnel. ASU will provide Dr. Qiang Chen, as Principal Investigator (“PI”) for work contemplated and performed under this Agreement.
  
 Period of Performance. This Agreement will begin on 1 September 2020 and will terminate on 30 November 2022. This Agreement may be modified or extended at any time by mutual written consent of both parties.
  
 Compensation. Compensation will be on a fixed-price basis. Sponsor will pay ASU in an amount not to exceed $1,371,782 for ASU's services hereunder.  Sponsor will remit not less than
 $21,782 upon execution by both parties of this Agreement, which ASU may hold as a reserve. The balance of the contract price due under this Agreement will be paid according to the following schedule:
  
 Payment Schedule
  
 	 Date Due:
	 Description of Deliverable:
	 Amount Due:

	 Upon Execution of Agreement
	 Fully Executed Agreement
	 $21,782

	 30th of each month
	 Monthly Payment (27 in Total)
	 $50,000

 
 
  
  
  
 	 Industry Sponsored Research Agreement – Fixed Price
	 Page 1

 
 
  
 
 	 
	
	

	 

 
 
  
 
 Sponsor acknowledges and agrees that ASU is not obligated to commence work until ASU has received the initial payment in the amount of $21,782. Invoices are due and payable within 30 days.
  
 ASU reserves the right to subject invoices not paid within thirty (30) days of the invoice date to a 1% per month late fee on the unpaid balance for any amounts not in dispute. ASU reserves the right to discontinue the services if Sponsor fails to make payments within 30 days of receipt of invoice.
  
 In the event of non payment, ASU may terminate all further work on the Project and seek full payment from the Sponsor for all work performed and all expenses incurred including allocable costs, pursuant to the termination clause of this Agreement including the collection of payment.
  
 If it becomes necessary for ASU to commence collection proceedings or retain an attorney to enforce any of the terms of this Agreement, the Sponsor will pay the attorneys’ fees and the costs of collection incurred by ASU.
  
 Questions regarding payment should be directed to cashmanagement@asu.edu.
  
 Invoices will be mailed to the Sponsor Financial Contact at the following address:
   
  
 	  
	 Halberd Corporation

	  
	 Attention:
	 Heidi Carl

	  
	 Address:
	 P.O. Box 25

	  
	 Phone:
	 814-786-8849

	  
	 Email:
	 HeidiCarl11@aol.com

 
 
  
 
 Publications. Sponsor recognizes that under ASU policy the results of work performed under this Agreement must be publishable and agrees that ASU and its employees and students engaged in work under this Agreement will be free to present at symposia or professional meetings, and to publish in journals, theses or dissertations, or otherwise of their own choosing, methods and results of the work performed under this Agreement. Upon written request by Sponsor, copies of proposed manuscripts  will be furnished to Sponsor for review  prior to publication. In no event will ASU delay publication for more than thirty (30) days from date of submittal of manuscript for Sponsor review.
  
 Consistent with its disclosure obligations as a public company, Sponsor will be permitted, to identify ASU as the research organization. Sponsor will allow ASU the opportunity for a one business day review of/revision to content of such press releases prior to distribution. Sponsor’s press releases will not specifically identify by name any ASU investigators/researchers without the express written permission from ASU.
   
  
 	 Industry Sponsored Research Agreement – Fixed Price
	 Page 2

 
 
  
 
 	 
	
	

	 

 
 
  
 
 Notices. All notices under this Agreement given by either party to the other will be in writing and will be sent by U.S. Postal Service, first class, facsimile or e-mail. Addresses are as follows:
   
  
 	  
	 For ASU:
	 Office for Research & Sponsored Projects Administration 
 Arizona State University
 P.O. Box 876011
 Tempe, Arizona   85287-6011 
 e-mail: asu.awards@asu.edu

	  
	  
	  

	  
	  
	 With copy to:
 Office of Industry Research & Collaborations 
 Arizona State University, SkySong – Suite 200 
 1475 N. Scottsdale Road
 Scottsdale, Arizona 85257-3538
 Fax: (480) 884-1984

	  
	  
	  

	  
	 For Sponsor:
	 Halberd Corporation
 William A. Hartman
 P.O. Box 25, Jackson Center, PA 16133 
 814-786-8849 
 WillialAHartman@aol.com

	  
	  
	  

	  
	  
	 With copy to:
 [Insert Additional Sponsor Contact Information if Applicable]

 
 
  
 
 Confidentiality. The parties may, at their discretion, and in connection with work contemplated or performed under this Agreement, disclose their respective proprietary or confidential information (“Confidential Information”) to each other. To be protected hereunder, Confidential Information must be marked confidential if disclosed in written or other tangible form. If Confidential Information is disclosed orally or visually, Confidential Information must be identified as confidential at the time of disclosure and reduced to writing, marked confidential, and transmitted to the receiving party within thirty (30) days of the initial disclosure.
  
 Nothing in this Agreement will be construed to convey to either party any right, title or interest in any Confidential Information provided by the other party or any right, title or interest in any intellectual property of the parties, including but not limited to, processes, copyrights or patents. No license to the receiving party under any trademark, patent or copyright is either granted or implied by the conveying of Confidential Information to the receiving party.
  
 The receiving party will not use, or disclose to any third party, Confidential Information of the disclosing party in any manner except for the purposes of this Agreement, and will require that its employees and agents (in the case of ASU, including employees of SkySong Innovations (“SI”)) who have access to such information maintain the same in strict confidence subject to the same restrictions. By way of example, but not limitation, the receiving party will not use Confidential Information of the disclosing party in connection with any patent application, for any commercial purpose, or for the benefit of any third party.
   
  
 	 Industry Sponsored Research Agreement – Fixed Price
	 Page 3

 
 
  
 
 	 
	
	

	 

 
 
  
 
 The parties will use reasonable efforts to prevent the disclosure to unauthorized third parties of any Confidential Information of the other party and will use such information only for the purposes of this Agreement. The receiving party’s obligations with respect to Confidential Information will survive for three (3) years after the termination of this Agreement; provided that the receiving party's obligations hereunder will not apply if the receiving party can show, with convincing written evidence, that the Confidential Information of the disclosing party received under this Agreement:
  
  
 	  
	 a)
	 was already known to the receiving party prior to the time of first disclosure; or

	  
	  
	  

	  
	 b)
	 at the time of disclosure is in the public domain, or after the date of the disclosure, lawfully becomes a part of the public domain other than through breach of this Agreement by the receiving party; or

	  
	  
	  

	  
	 c)
	 is received in good faith, without any obligation of confidentiality from a third party having a legal right to disclose the same; or

	  
	  
	  

	  
	 d)
	 is independently developed by the receiving party by individuals without access to such information; or

	  
	  
	  

	  
	 e)
	 is required to be disclosed by the receiving party pursuant to a legally enforceable order, law, subpoena, or other regulation (“Order”), provided, however, that the receiving party promptly notifies the disclosing party in advance of such disclosure and discloses only that Information necessary to comply with said Order.

 
 
  
  
 ASU retains the right to refuse acceptance of any Confidential Information that is not required for the purposes of this Agreement.
  
 Notwithstanding any  other provision of this Agreement to the contrary, ASU is a public institution, and as such is subject to A.R.S. §§ 39-121 through 39-127 regarding public records. Any provision regarding confidentiality is limited to the extent necessary to comply with the provisions of Arizona law.
  
 Export Control.
 Sponsor agrees to give ASU express advance written notice prior to providing ASU any export controlled information, technology, software, equipment or know-how so ASU can take the appropriate measures. All export controlled information, technology, software, equipment or know-how furnished by the Sponsor shall  be appropriately marked as “export controlled”. Sponsor agrees to furnish ASU only export controlled information that ASU needs to complete its work under this Agreement. ASU shall have the right to refuse acceptance of export controlled information.
  
 Intellectual Property.
  
 	  
	 General. Subject to any obligations to the United States Government pursuant to the provisions of 35 U.S.C. sections 200-212 and applicable regulations of Chapter 37 of the Code of Federal Regulations:

	  
	  
	  

	  
	 a)
	 Intellectual Property resulting from the performance of the Project and created solely by legal inventors or authors who are ASU employees will be owned by ASU (“ASU IP”) and managed through SI.

	  
	  
	  

	  
	 b)
	 Intellectual Property resulting from the performance of the Project and created solely by legal inventors or authors who are Sponsor’s employees will be owned by Sponsor (“Sponsor IP”).

 
 
  
  
  
 	 Industry Sponsored Research Agreement – Fixed Price
	 Page 4

 
 
  
 
 	 
	
	

	 

 
 
  
 
  
 	  
	 c)
	 Intellectual Property resulting from the performance of the Project and created jointly by legal inventors who are ASU’s employees and Sponsor’s employees will be owned jointly by ASU, managed by SI, and Sponsor (“Joint IP”).

	  
	  
	  

	  
	 d)
	 ASU and Sponsor shall retain ownership of all intellectual property and materials owned by each of them prior to the Effective Date.

	  
	  
	  

	  
	 d)
	 “Intellectual Property” means any inventions, discoveries, concepts, methods, processes, data, copyrights, computer programs and related documentation, works of authorship fixed in a medium of expression, or mask works, whether or not patentable, copyrightable or subject to mask work rights or other similar statutory rights, as well as applications for any such rights.

 
 
  
  
  
 	  
	 Patent Applications. Patent applications will be filed by SI on behalf of ASU on ASU IP and Joint IP. Sponsor may, at any time, request SI to file a patent application on ASU IP or Joint IP.

	  
	  
	  

	  
	 a)
	 If such a request is made, Sponsor agrees to reimburse SI for all patent costs plus a 15% patent administration charge. In addition, Sponsor has the right to review all filings and office actions related to the patent applications, provided, however, that in an emergency when immediate action is needed to protect ASU IP or Joint IP, documents may be filed prior to review by the Sponsor and in such event, telephone or facsimile notice shall be given promptly by SI or SI’s counsel of such action. SI will use reasonable efforts to avoid emergency situations in cases where they have control over the timing of steps involved in protecting ASU IP or Joint IP.

 
 
  
  
  
 	  
	 Option. In consideration of Sponsor’s support of this Project and to the extent that SI has a right to grant such license, Sponsor shall be entitled to an option to negotiate a royalty- bearing license to ASU IP and/or ASU’s interest in Joint IP, so long as Sponsor agrees to reimburse SI for all patent costs plus a 15% patent administration charge during the term of the option. Failure to reimburse SI’s patent costs plus a 15% patent administration charge will result in termination of the option.

	  
	  
	  

	  
	 a)
	 Sponsor must exercise the option in writing to SI within thirty (30) days of SI’s notification to Sponsor of any invention/discovery or within thirty (30) days of the termination of the Project, whichever occurs sooner.

	  
	  
	  

	  
	 b)
	 A license must be negotiated in good faith within three (3) months of Sponsor’s written notification that it wishes to exercise the option. Said license shall contain reasonable terms that are standard in the industry for the ASU IP and/or ASU’s interest in Joint IP, shall require diligent performance by Sponsor for the timely commercial development and marketing of such ASU IP and/or ASU’s interest in Joint IP, and shall include Sponsor’s obligation to reimburse SI’s patent costs plus a 15% patent administration charge for all inventions subject to the license.

	  
	  
	  

	  
	 Disclosure. Sponsor shall retain all invention disclosures submitted  by ASU or SI in confidence and use its best efforts to prevent disclosure to third parties. Sponsor shall be relieved of this obligation only when this information becomes publicly available through no fault of Sponsor.

 
 
  
  
  
 	 Industry Sponsored Research Agreement – Fixed Price
	 Page 5

 
 
  
 
 	 
	
	

	 

 
 
  
 
 Entire Agreement; Amendments; Counterparts. This Agreement constitutes the entire understanding between the parties relating to the subject matter hereof, and supersedes any other agreement or understanding between the parties. No amendment or modification to this Agreement will be valid or binding upon the parties unless made in writing and signed by each party. This Agreement may be executed in counterparts, each of which will be deemed an original. The parties agree that should any part of this Agreement be held to be invalid or void, the remainder of the Agreement will remain in full force and effect and will be binding upon the parties. Facsimile transmitted and imaged copy signatures will be fully binding and effective for all purposes.
  
 Waivers. No waiver of this Agreement will be valid or binding unless written and signed by the parties. Waiver by either party of any breach or default of any clause of this Agreement by the other party will not operate as a waiver of any previous or future default or breach of the same or different clause of this Agreement.
  
 Assignment. Neither party may assign any rights hereunder without the express, written, prior consent of both parties.
  
 Governing Law. This Agreement will be governed by and construed in accordance with the laws of the State of Arizona. In addition, ASU’s obligations hereunder are subject to the laws of the State of Arizona and the policies of the Arizona Board of Regents.
  
 Cancellation for Nonappropriations. In accordance with A.R.S. § 35-154, if ASU’s performance under  this Agreement depends on the appropriation of  funds by the Arizona Legislature, and if the Legislature fails to appropriate the funds necessary for performance or reduces ASU’s appropriation during the fiscal year, then ASU may provide written notice of this to Sponsor and reduce the scope of this Agreement or cancel this Agreement without further obligation of ASU. Appropriation is a legislative act and is beyond the control of ASU.
  
 Conflict of Interest. In accordance with A.R.S. § 38-511, ASU may cancel this Agreement within three years after the execution of this Agreement, without penalty or further obligation, if any person significantly involved in initiating, negotiating, securing, drafting, or creating this Agreement on behalf of ASU, at any time while this Agreement or any extension thereof is in effect, becomes an employee or agent of the other party to this Agreement in any capacity or a consultant to any other party with respect to the subject matter of this Agreement.
  
 Independent Contractor. ASU is an independent contractor and will be free to exercise its discretion and independent judgment as to the method and means of performance of its work hereunder. ASU employees will not be considered employees of Sponsor, and neither ASU nor Sponsor personnel will, by virtue of this Agreement, be entitled or eligible, to participate in any benefits or privileges given or extended by the other party to its employees.
  
 Termination. Either party may at any time terminate this Agreement by giving the other party not less than thirty (30) days prior written notice. In the event this Agreement is canceled by Sponsor, Sponsor will remain responsible for payment to ASU for all work performed through the date of termination and for reimbursement to ASU of all non-cancelable commitments incurred in the conduct of the research. Non-cancelable commitments will include employment commitments to ASU personnel through the end of the semester following any such termination by Sponsor. In the event ASU terminates this Agreement any unused funds from the advance will be returned.
   
  
 	 Industry Sponsored Research Agreement – Fixed Price
	 Page 6

 
 
  
 
 	 
	
	

	 

 
 
  
 
 Force Majeure.
  
 With the exception of a party’s payment obligations, no liability shall result from the delay in performance or nonperformance caused by force majeure or circumstances beyond the reasonable control of the party affected, including, but not limited to, acts of God, fire, flood, substantial snowstorm or other weather condition, war, terrorism, embargo, any United States or foreign government regulation, direction or request, accident, disease, pandemic or epidemic, strike or other labor dispute or labor trouble, civil unrest, or any failure or delay of any transportation, power, equipment or communications system, other emergencies that disrupt a party’s operations, or any other or similar cause beyond that party’s reasonable control.
  
 The party which is so prevented from performing shall give prompt notice to the other party of the occurrence of such event of force majeure, the expected duration of such condition and the steps which it is taking to correct such condition. This Agreement may be terminated by either party by written notice upon the occurrence of such event of force majeure which results in a delay of performance hereunder exceeding thirty (30) days.
  
 Dispute Resolution.  In the event of any dispute, claim, question, or disagreement arising from or relating to this Agreement or the breach thereof, the parties hereto will use their reasonable efforts to settle the dispute, claim, question, or disagreement. To this effect, they will consult and negotiate with each other in good faith and, recognizing their mutual interests, attempt to reach a just and equitable solution satisfactory to both parties The Parties acknowledge that disputes arising from this Agreement may be subject to non-binding arbitration in accordance with applicable state law and court rules.
  
 Insurance. ASU maintains general liability insurance and worker’s compensation coverage as required by state law and pertinent federal laws and regulations under the State of Arizona Risk Management Plan.
  
 Nondiscrimination. The parties agree to comply with all applicable state and federal laws, rules, regulations and executive orders governing equal employment opportunity, immigration, nondiscrimination, including the Americans with Disabilities Act. If applicable, the parties will abide by the requirements of 41 CFR §§ 60-1.4(a), 60-300.5(a) and 60-741.5(a). These regulations prohibit discrimination against qualified individuals based on their status as protected veterans or individuals with disabilities, and prohibit discrimination against all individuals based on their race, color, religion, sex, or national origin. Moreover, these regulations require that covered prime contractors and subcontractors take affirmative action to employ and advance in employment individuals without regard to race, color, religion, sex, national origin, protected veteran status or disability.
  
 Advertising, Publicity, Names And Marks. Sponsor will not do any of the following, without, in each case, ASU’s prior written consent: (i) use any names, service marks, trademarks, trade names, logos, or other identifying names, domain names, or identifying marks of ASU (ASU Marks), including online, advertising, or promotional purposes; (ii) issue a press release or public statement regarding this Agreement, except for documents used for internal consumption by Sponsor; or (iii) represent or imply any ASU endorsement or support of any product or service in any public or private communication. Any permitted use of ASU Marks must comply with ASU’s requirements, including using the ® indication of a registered mark.
  
 * * * Signature Page to Follow * * *
   
  
 	 Industry Sponsored Research Agreement – Fixed Price
	 Page 7

 
 
  
 
 	 
	
	

	 

 
 
  
 
 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their duly authorized representatives on the respective dates entered below.
  
  
 	 Arizona Board of Regents for and on behalf
 of Arizona State University
	  
	 Sponsor
	  

	  
	 	 	 	 	 
	 By:
	 /s/ Kristy Macdonald
	 	By:	 /s/ William A. Hartman
	 
	  
	  
	  
	  
	  
	  

	 Name:
	Kristy Macdonald	 	Name:	William A. Hartman	 
	  
	  
	  
	  
	  
	  

	 Title:
	Assistant Director	 	Title:	Chairman, President & CEO	 
	  
	  
	  
	  
	  
	  

	 Date:
	August 27, 2020	  
	 Date:
	 August 23, 2020
	  

 
 
  
  
  
 	 Industry Sponsored Research Agreement – Fixed Price
	 Page 8

 
 
  
 
 	 
	
	

	 

 
 
  
 
 INDUSTRY SPONSORED RESEARCH AGREEMENT
 FIXED PRICE
 Exhibit A: Scope of Work
  
 University Project Description
 Possible project(s) with the University Partner.  The specific project could be delineated after a series of meetings and discussions.  All of these projects are based upon the Marv IP-two granted patents and three provisional patent applications.
  
 The University project for a rapid test to identify Covid-19 infection, from a sample such as saliva, mucus, blood and CSF  will be based upon the following two IP applications: Method for Treating and Curing Covid-19 Infection , and  Method for the Rapid Identification of Covid-19 Infection.
  
 The prerequisites for the project would be:
  
  
 	  
	 1.
	 The Principle Investigator agrees with the viability of the project

	  
	  
	  

	  
	 2.
	 A patent attorney agrees with the potentiality for obtaining patentability of the developed IP

	  
	  
	  

	  
	 3.
	 A Ph.D. in pharmacology agrees with the viability of any therapeutic modality 

 
 
  
 
 The targeted antigen(s)/TA(s) of Covid-19 which will be the focus of the project :
  
 Covid-19 spike glycoprotein, Covid-19 M-Protein, Covid-19 Hemoglutin-esterase dimer, Covid-19 Envelope, Covid-19 E-Protein, Covid-19 N-Protein, nsp (non-structural protein) 12 RNA-dependent RNA polymerase (nsp 12), nsp (non-structural protein) 7, nsp 8, nsp 14, nsp 12-nsp 7-nsp 8 complex, nsp7-nsp8 complex, nsp10-nsp14 complex, and nsp10-nsp16 complex.
  
 There will be a focus on one or more of the following Projects, possibly in combination, in order to achieve a successful methodology for identifying a positive Covid-19 sample, with a high degree of certainty, and as rapidly as possible:
  
  
 	  
	 1.
	 Creation of a unique Covid-19 fluorescent antibody which contains an albumin moiety and targets the rapid identification of the Covid-19 target antigens

	  
	  
	  

	  
	 2.
	 The investigation of a method using dialysis, or a variant of dialysis, to remove the fluorescent antibody-antigen complex, for the rapid identification of a Covid- 19 sample

	  
	  
	  

	  
	 3.
	 The investigation of a method utilizing a designer fluorescent antibody with an attached macromolecular moiety. The macromolecular moiety, attached to the antibody, would be 1.000 mm to 0.00001 mm in diameter. The antibody- macromolecular moiety-targeted antigen complex would then be blocked for analysis , by using a series of microscreens which contain openings with a diameter 50.00000% to 99.99999% less than the diameter of the designer antibody-macromolecular moiety.

 
 
  
  
  
 	Industry Sponsored Research Agreement – Fixed Price – Exhibit A	 Page 1

 
 
  
 
 	 
	
	

	 

 
 
  
 
  
 	  
	 4.
	 The investigation of a methodology comprising the removal of the targeted antigen(s)/TA(s) by using a designer fluorescent antibody containing an iron (Fe) moiety. This will then create an Fe-fluorescent Antibody-Antigen (Covid- 19/virion) complex. This iron containing complex would then be efficaciously removed using a strong, localized magnetic force field, which could easily be identified as positive.

	  
	  
	  

	  
	 5.
	 The investigation of a variant of gel filtration chromatography, which would be utilized for the rapid identification of Covid-19. The fluorescent antibody-target antigen would be used to transport the sample through a size exclusion column that would be used to separate the fluorescent antibody-target antigen by size and molecular weight.

	  
	  
	  

	  
	 6.
	 The investigation of a methodology which would utilize a molecular weight cut- off filtration. Molecular weight cut-off filtration refers to the molecular weight at which at least 80% of the target antigen(s)/TA(s) is prohibited from membrane diffusion.

	  
	  
	  

	  
	 7.
	 There would be the investigation of a removal methodology for the fluorescent antibody-target antigen(s). The removal methodology would be selected from a group comprising a mechanical filter, a chemical filter, a dialysis machine, a molecular filter, molecular adsorbent recirculating system (MARS), a plasmapheresis unit, or combinations thereof.

	  
	  
	  

 
 
  
  
 At the conclusion of each project, ASU and Sponsor will meet to review results and mutually agree on next step/phase/project direction, or termination of future projects.
  
 Molecular adsorbents recirculating system (MARS), may be compatible and/or synergistic with dialysis equipment. MARS technology may be used to remove small to average sized molecules from the sample. The removal methodology will be any device capable of removing the fluorescent antibody-antigen complex for analysis.
  
 Additional embodiments to be considered in this methodology would include continuous renal replacement therapy (CRRT) which can remove filterable molecules from the sample. CRRT would be particularly useful for molecular compounds that are not strongly bound to plasma proteins. Categories of CRRT include continuous arteriovenous hemofiltration, continuous venovenous hemofiltration, continuous arteriovenous hemodiafiltration, slow continuous filtration, continuous arteriovenous
 high-flux hemodialysis, and continuous venovenous high flux hemodialysis. Tthe removal module is selected from a group comprising a mechanical filter, a chemical filter, a dialysis machine, a molecular filter, molecular adsorbent recirculating system (MARS), a plasmapheresis unit, or combinations thereof.
  
  
 	 I.
	 Antibodies for targeted antigens:

 
 
  
 
  
 	  
	 a)
	 Spike (S) protein, N protein.

 
 
  
  
  
 	Industry Sponsored Research Agreement – Fixed Price – Exhibit A	 Page 2

 
 
  
 
 	 
	
	

	 

 
 
  
 
  
 	  
	 b)
	 Other antigens: E, M, NSPs need longer time to develop as it takes more times to produce and purify these antigens

 
 
  
 
  
 	 II.
	 Projects in Dr. Hartman’s Project Scope that are feasible at ASU are listed below. If specific supports are need to accomplish a project, they are described after that project.

 
 
  
 
 Projects 
  
 	 1.
	 #1

	 2.
	 #3: need a detailed method to attached the macromolecular moiety to the designer fluorescent antibody

	 3.
	 #4: need a detailed method to attached the iron moiety to the designer fluorescent antibody

	 4.
	 #5

	 5.
	 #6

 
 
  
 
 Project #2 and #7 are not feasible at ASU, as we do not have the equipment or expertise in using the dialysis machine.
  
  
 	 III.
	 Project stage and timeline:

 
 
  
 
  
 	 1.
	 Generate antigens: 1 or 4 months

 
 
  
 
 	  
	 a)
	 1 month (if only S and N)

	  
	 b)
	 or 4 months (if E, M and one NSP antigen)

 
 
  
 
 	 2.
	 generate mAbs from antigens: 6 months

 
 
  
 
 	  
	 a)
	 hybridoma generation

	  
	 b)
	 hybridoma screen

	  
	 c)
	 sequence hybridoma

	  
	 d)
	 recombinant mAb expression

	  
	 e)
	 recombinant mAb purification

 
 
  
 
 	 3.
	 in vitro mAb characterization: 2 months

	 4. 
	 create an fluorescent antibody with an albumin moiety: 3 months

 
 
  
 
 	  
	 a)
	 molecular construction: 1 month

	  
	 b)
	 expression and purification: 1 month

	  
	 c)
	 characterize the fluorescent antibody: 1 month

 
 
  
 
 	 5.
	 project 3: 3 months

	 6.
	 project 4: 3 months

	 7.
	 Project 5: 3 months

	 8.
	 Project 6: 3 months

 
 
  
 
 Projects in 5-8 can be done sequentially by the current personnel or in parallel if more scientists are hired.
  
 	 IV.
	 Personnel: Dr. Shawn Chen, Dr. Adrian Esqueda, Collin Jugler, Dr. Haiyan Sun,

	 V.
	 Budget: $29K direct cost (Personnel, Material and supplies, Animal charge, Service) + $21K indirect cost = $50 K per month

 
 
  
  
  
 	Industry Sponsored Research Agreement – Fixed Price – Exhibit A	 Page 3

 
 
  
 
 	 
	
	

	 

 
 
  
 
 MASTER AGREEMENT
  
 NO.           020821           
  
 THIS MASTER AGREEMENT (“Agreement”) is made and entered into by and between Halberd Corporation, a publicly traded company, having a place of business at P.O. Box 25, Jackson Center, PA 16133 (“Sponsor”), and the Greenbio AZ Inc (GREENBIO), an affiliate of Arizona State University (ASU), whose principal location is Chandler, Arizona.
  
 This Master Agreement specifies the mutual understanding of the parties with regards to Sponsor engaging GREENBIO to perform research projects within the General Scope of Work set forth  in Exhibit A hereto. Individual research projects (“IRP”), (e.g. IRP020821-1 in Exhibit B), shall be authorized via separate Scopes of Work issued by the Sponsor to GREENBIO under this Agreement.  The terms and conditions of each IRP issued under this Agreement shall be agreed upon by the parties. This Master Agreement is in addition to, supplemental to, and to be worked under the auspices of, and in coordination with, the August 27, 2020 Sponsored Research Agreement between the Sponsor and Arizona State University, ASU Reference No. FP00026198 (the “ASU Agreement”). Nothing in this Agreement is in conflict with, or otherwise violative of, the ASU Agreement.
  
 NOW, THEREFORE, the parties agree as follows:
  
 ARTICLE I.  SCOPE OF WORK. GREENBIO shall use all reasonable efforts to perform the research and deliver any reports or other items specified in each IRP issued under this Agreement. The research will be performed at the facilities of and under the auspices of, and with full disclosure to, ASU.
  
 ARTICLE II. PRINCIPAL INVESTIGATOR.  GREENBIO shall identify for each IRP a Principal Investigator for that specific project. That Principal Investigator shall work in coordination with Dr. Qiang "Shawn" Chen, Ph.D. and his efforts pursuant to the ASU Agreement.
  
 ARTICLE III.  AGREEMENT TERM.  This Agreement shall be effective on the date of the last signature hereto, and terminate on June 30, 2021.  Any IRP issued under this Agreement during the term shall be effective for the period set forth in the IRP even if said period extends beyond the term of this Agreement. This Agreement term may be modified or extended at any time by mutual written consent of both parties.
  
  
 		 Page 1

 
 
  
 
 	 
	
	

	 

 
 
  
 
 ARTICLE IV. SPECIAL PROVISIONS.
  
 1. Compensation. Compensation for each IRP issued by Sponsor to GREENBIO hereunder shall be on a fixed price basis and specified in each IRP. Sponsor shall remit one hundred percent (100%) of the total IRP amount upon agreement by both parties on each IRP.
  
 GREENBIO reserves the right to discontinue the Services under an IRP if Sponsor fails to make payments within ten (10) days of the starting date of an IRP .
  
 In the event of non-payment, GREENBIO may terminate all further work on an IRP and seek full payment from the Sponsor for all work performed and all expenses incurred including allocable costs, pursuant to the termination clause of this agreement including the collection of payment.
  
 Should it become necessary for GREENBIO to commence collection proceedings or retain an attorney to enforce any of the terms of this Agreement, the Sponsor shall pay attorneys’ fees and the costs of collection incurred by GREENBIO.
  
 Please send checks or paper remittance advices to: 
  
 GreenBio AZ INC
 123 Drummond Farms Ln 
 Newark, DE 19711
  
 Wire transfers should be sent to: 
  
  
  
 Questions should be directed to the person issuing the invoice or to greenbioaz.acctg@gmail.com
  
 2. Publications. Sponsor recognizes that under GREENBIO policy the results of work performed under this Agreement must be publishable and agrees that GREENBIO and its employees engaged in work under this Agreement shall be free to present at symposia or professional meetings, and to publish in journals, theses or dissertations, or otherwise of their own choosing, methods and results of the work performed under this Agreement. Upon written request by Sponsor, copies of proposed manuscripts will be furnished to Sponsor for review prior to publication. Sponsor reserves the right to request removal of any material that includes Confidential Information of Sponsor. In no event will GREENBIO delay publication for more than thirty (30) days from date of submittal of manuscript for Sponsor review.
  
  
 		 Page 2

 
 
  
 
 	 
	
	

	 

 
 
  
 
 3. Notices. All official notices, by either party, required or permitted under this Agreement will be in writing and will be given by personal delivery against receipt (including private courier such as FedEx), email with “Read Receipt” or certified U.S. Mail, return receipt requested. All notices will be sent to the addresses below or such other addresses as the parties may specify in the same manner. Notices will be deemed to have been given and received on the date of actual receipt or on the date receipt was refused. Courtesy email copy of any notice is requested to be sent to the PI. Addresses are as follows:
   
  
 	 GreenBio AZ INC
 123 Drummond Farms Ln
 P.O. Box 876011
 Newark DE 19711
 greenbioaz.acctg@gmail.com
 (302) 763-2646
	  
	 For Sponsor:
 William A. Hartman
 Halberd Corporation
 P.O. Box 25
 Jackson Center, PA 16133
 WillialAHartman@aol.com
 (814)-786-8849

 
 
  
 
 cc: PI email address: Shawn.q.chen@gmail.com
  
 4. Intellectual Property.
  
  
 	  
	 a)
	 a) Intellectual Property resulting from the performance of IRPs under this Agreement and created solely by legal inventors or authors who are GREENBIO employees will be owned by GREENBIO (“GREENBIO IP”), the financial benefits for which shall accrue to the Sponsor but subject to a 5% royalty to GREENBIO or its designees, as in the case of the ASU Master Agreement.Intellectual Property resulting from the performance of IRPs under this Agreement and created solely by legal inventors or authors who are Sponsor’s employees will be owned by Sponsor (“Sponsor IP”), but subject to a 5% royalty to GREENBIO or its designees, as in the case of the ASU Master Agreement.

	  
	  
	  

	  
	 b)
	 Intellectual Property resulting from the performance of IRPs under this Agreement and created jointly by legal inventors who are GREENBIO’s employees and Sponsor’s employees will be owned jointly by GREENBIO, and Sponsor (“Joint IP”).

	  
	  
	  

	  
	 d)
	 GREENBIO and Sponsor shall retain ownership of all intellectual property and materials owned by each of them prior to the date hereof.

	  
	  
	  

	  
	 e)
	 “Intellectual Property” shall mean any inventions, discoveries, concepts, methods, processes, data, copyrights, computer programs and related documentation, works of authorship fixed in a medium of expression, or mask works, whether or not patentable, copyrightable or subject to mask work rights or other similar statutory rights, as well as applications for any such rights.

 
 
  
 
  
 	  
	2)	 PATENT APPLICATIONS. Patent applications will be filed by GREENBIO on GREENBIO IP and Joint IP. Sponsor may, at any time, request to file a patent application on GREENBIO IP or Joint IP. In either case, the parties shall jointly participate in that process.

 
 
  
 
  
 		 Page 3

 
 
  
 
 	 
	
	

	 

 
 
  
 
  
 	  
	 3)
	 OPTION. In consideration of Sponsor’s support of this Project, Sponsor shall be entitled to an option to negotiate a royalty-bearing license of 5% to GREENBIO IP and/or GREENBIO’s interest in Joint IP, so long as Sponsor agrees to reimburse GREENBIO for all patent costs plus a 15% patent administration charge during the term of the option. Failure to reimburse patent costs plus a 15% patent administration charge will result in termination of this option.

 
 
  
  
  
 	  
	 a)
	 Sponsor must exercise the option in writing to GREENBIO within thirty (30) days of GREENBIO’s notification to Sponsor of any invention/discovery or within thirty (30) days of the termination of the Project, whichever occurs sooner.

	  
	  
	  

	  
	 b)
	 Aside from the rate itself, the specific terms of any license must be negotiated in good faith within three (3) months of Sponsor’s written notification that it wishes to exercise the option. Said license shall contain reasonable terms that are standard in the industry for the GREENBIO IP and/or GREENBIO’s interest in Joint IP, shall require diligent performance by Sponsor for the timely commercial development and marketing of such GREENBIO IP and/or GREENBIO’s interest in Joint IP, and shall include Sponsor’s obligation to reimburse GREENBIO’s patent costs plus a 15% patent administration charge for all inventions subject to the license.

 
 
  
 
  
 	  
	 4) 
	 DISCLOSURE. Sponsor shall retain all invention disclosures submitted by GREENBIO in confidence and use its best efforts to prevent disclosure to third parties. Sponsor shall be relieved of this obligation only when this information becomes publicly available through no fault of Sponsor. Consistent with its duties as a public company, Sponsor will issue press releases and engage in social media.

 
 
  
 
 5. Confidentiality. The parties may, at their discretion, and in connection with work contemplated or performed under this Agreement, disclose their respective proprietary or confidential information (“Confidential Information”) to each other. To be protected hereunder, Confidential Information must be marked confidential if disclosed in written or other tangible form. If Confidential Information is disclosed orally or visually, Confidential Information must be identified as confidential at the time of disclosure and reduced to writing, marked confidential, and transmitted to the receiving party within thirty (30) days of the initial disclosure.
  
 Nothing in this Agreement will be construed to convey to either party any right, title or interest in any Confidential Information provided by the other party or any right, title or interest in any intellectual property of the parties, including but not limited to, processes, copyrights or patents. No license to the receiving party under any trademark, patent or copyright is either granted or implied by the conveying of Confidential Information to the receiving party.
  
 The receiving party will not use, or disclose to any third party, Confidential Information of the disclosing party in any manner except for the purposes of this Agreement, and will require that its employees and agents who have access to such information maintain the same in strict confidence subject to the same restrictions. By way of example, but not limitation, the receiving party will not use Confidential Information of the disclosing party in connection with any patent application, for any commercial purpose, or for the benefit of any third party.
  
  
 		 Page 4

 
 
  
 
 	 
	
	

	 

 
 
  
 
 The parties will use reasonable efforts to prevent the disclosure to unauthorized third parties of any Confidential Information of the other party and will use such information only for the purposes of this Agreement. The receiving party’s obligations with respect to Confidential Information will survive for three (3) years after the termination of this Agreement; provided that the receiving party's obligations hereunder will not apply if the receiving party can show, with convincing written evidence that the Confidential Information of the disclosing party received under this Agreement:
  
  
 	  
	 a)
	 was already known to the receiving party prior to the time of first disclosure; or

	  
	  
	  

	  
	 b)
	 at the time of disclosure is in the public domain, or after the date of the disclosure, lawfully becomes a part of the public domain other than through breach of this Agreement by the receiving party; or

	  
	  
	  

	  
	 c)
	 is received in good faith, without any obligation of confidentiality from a third party having a legal right to disclose the same; or

	  
	  
	  

	  
	 d)
	 is independently developed by the receiving party by individuals without access to such information; or

	  
	  
	  

	  
	 e)
	 is required to be disclosed by the receiving party pursuant to a legally enforceable order, law, subpoena, or other regulation (“Order”), provided, however, that the receiving party promptly notifies the disclosing party in advance of such disclosure and discloses only that Information necessary to comply with said Order.

 
 
  
 
 GREENBIO retains the right to refuse acceptance of any Confidential Information that is not required for the purposes of this Agreement.
  
 ARTICLE V. GENERAL PROVISIONS.
  
 1. Entire Agreement; Amendments; Counterparts. This Agreement embodies the entire understanding of the parties and supersedes any other agreement or understanding between the parties relating to the subject matter. The parties agree that should any part of this Agreement be held to be invalid or void, the remainder of the Agreement shall remain in full force and effect and shall be binding upon the parties. This Agreement may be executed in counterparts, each of which will be deemed an original. Electrionically transmitted and imaged copy signatures will be fully binding and effective for all purposes.
  
 2. Waivers. No waiver, amendment or modification of this Agreement shall be valid or binding unless written and signed by the parties. Waiver by either party of any breach or default of any clause of this Agreement by the other party shall not operate as a waiver of any previous or future default or breach of the same or different clause of this Agreement.
   
  
 		 Page 5

 
 
  
 
 	 
	
	

	 

 
 
  
 
 3. Assignment. Neither party may transfer or assign this Agreement or any of other party’s rights or obligations hereunder, directly or indirectly, or by operation of law, without that party’s prior written consent, and any attempt to the contrary will be void.
  
 4. Governing Law and Venue. This Agreement will be governed by the laws of the State of Arizona without regard to any conflicts of laws principles. Any proceeding arising out of or relating to this Agreement will be conducted in Maricopa County, Arizona. Each party consents to such jurisdiction, and waives any objection it may have to venue or convenience of forum.
  
 5. Independent Contractor. GREENBIO is an independent contractor and will be free to exercise its discretion and independent judgment as to the method and means of performance of its work hereunder. GREENBIO employees will not be considered employees of Sponsor, and neither GREENBIO nor Sponsor personnel will, by virtue of this Agreement, be entitled or eligible, to participate in any benefits or privileges given or extended by the other party to its employees.
  
 6. Termination. Either party may at any time terminate this Agreement by giving the other party not less than thirty (30) days prior written notice. In the event this Agreement is canceled by Sponsor, Sponsor will remain responsible for payment to GREENBIO for all work performed through the date of termination and for reimbursement to GREENBIO of all non-cancelable commitments incurred in the conduct of the research. Non-cancelable commitments will include employment commitments to GREENBIO personnel through the end of the semester following any such termination by Sponsor. In the event GREENBIO terminates this Agreement any unused funds from the reserve will be returned.
  
 7. Dispute Resolution. In the event of any dispute, claim, question, or disagreement arising from or relating to this Agreement or the breach thereof, the parties hereto will use their reasonable efforts to settle the dispute, claim, question, or disagreement. To this effect, they will consult and negotiate with each other in good faith and, recognizing their mutual interests, attempt to reach a just and equitable solution satisfactory to both parties.
  
 * * * Signature Page Follows * * *
   
  
 		 Page 6

 
 
  
 
 	 
	
	

	 

 
 
  
 
 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by its duly authorized representatives on the respective dates entered below.
  
  
 	 GREENBIO
	  
	 Sponsor: Halberd Corporation
	  

	  
	  
	  
	  
	  
	  

	  
	 	 	 	 	 
	 By:
	/s/ Hong Hou	 	By:	/s/ William Hartman	 
	  
	  
	  
	  
	  
	  

	 Name:
	Hong Hou	 	Name:	William Hartman	 
	  
	  
	  
	  
	  
	  

	 Title:
	President	 	Title:	President, CEO	 
	  
	  
	  
	  
	  
	  

	 Date:
	 February 15, 2021
	  
	 Date:
	 February 12, 2021
	  

 
 
  
  
  
 		 Page 7

 
 
  
 
 	 
	
	

	 

 
 
  
 
 EXHIBIT A
 to GREENBIO Agreement No.             020821             
  
 Scope of Work
  
  
 	 1.
	 Producing metal-lablelled monoclonal antibody (mAb) against SARS-CoV-2.

	  
	  

	 2.
	 Testing the efficacy of metal-labelled mAb in eliminating SARS-CoV-2 by particular radio frequency.

 
 
  
  
  
 		 Page 8

 
 
  
 
 	 
	
	

	 

 
 
  
 
 EXHIBIT B
 to Master Agreement No.               020821               
  
 Individual Research Project (IRP) No. 020821-1 
 under
 Master Agreement No.               020821                
 Between
 The GREENBIO
 And 
 Halberd Corporation
  
 Per the Master Agreement effective 02/15/2021, this IRP, as specified in IRP Scope of Work attached hereto, is hereby authorized. The terms and conditions specific to this IRP are as follows:
  
  
 	 1. 
	 Funding total $ 40,000 (does not include cost associated with purchasing radio frequency (RF) equipment), payable $20,000 prior to the March 1, 2021 commencement and $20,000 on or before April 1, 2021.

	 2.
	 Period of Performance is from 03/01/2021 through 05/31/2021

	 3.
	 Scope of work

 
 
  
 
 	  
	 a)
	 Modify and activate iron-based nanoshell

	  
	 b)
	 Conjugte monoclonal antibody against E. coli to activate nanoshell

	  
	 c)
	 Characterize iron-labelled monoclonal antibody

	  
	 d)
	 Halberd will provide the RF equipment. Setup and calibrate RF system for biological samples.

	  
	 e)
	 Test the efficacy of iron-labelled monoclonal antibody in killing E. coli in solution by various radio frequencies

 
 
  
 
 All other provisions set forth in the aforementioned Agreement shall remain the same.
  
 IN WITNESS WHEREOF, the parties have caused this IRP to be executed by their duly authorized representatives. IRP effective the date of last signature by the authorized representatives.
   
  
 	 Halberd Corporation
	  
	 GREENBIO
	  

	  
	  
	  
	  

	  
	  
	  
	  

	 NAME
	  
	 NAME
	  

	 Title
	  
	 Title
	  

	  
	  
	  
	  

	 Date: ___________________________
	  
	 Date: ___________________________
	  

 
 
  
  
  
 		 Page 9

 
 
  
 
 	 
	
	

	 

 
 
  
 
 MASTER AGREEMENT
  
 NO.             020821             
  
 THIS MASTER AGREEMENT (“Agreement”) is made and entered into by and between Halberd Corporation, a publicly traded company, having a place of business at P.O. Box 25, Jackson Center, PA 16133 (“Sponsor”), and the Greenbio AZ Inc (GREENBIO), an affiliate of Arizona State University (ASU), whose principal location is Chandler, Arizona.
  
 This Master Agreement specifies the mutual understanding of the parties with regards to Sponsor engaging GREENBIO to perform research projects within the General Scope of Work set forth in Exhibit A hereto. Individual research projects (“IRP”), (e.g. IRP020821-1 in Exhibit B), shall be authorized via separate Scopes of Work issued by the Sponsor to GREENBIO under this Agreement. The terms and conditions of each IRP issued under this Agreement shall be agreed upon by the parties. This Master Agreement is in addition to, supplemental to, and to be worked under the auspices of, and in coordination with, the August 27, 2020 Sponsored Research Agreement between the Sponsor and Arizona State University, ASU Reference No. FP00026198 (the “ASU Agreement”). Nothing in this Agreement is in conflict with, or otherwise violative of, the ASU Agreement.
  
 NOW, THEREFORE, the parties agree as follows:
  
 ARTICLE I. SCOPE OF WORK. GREENBIO shall use all reasonable efforts to perform the research and deliver any reports or other items specified in each IRP issued under this Agreement.
  
 ARTICLE II.PRINCIPAL INVESTIGATOR. GREENBIO shall identify for each IRP a Principal Investigator for that specific project. That Principal Investigator shall work in coordination with Dr. Qiang "Shawn" Chen, Ph.D. and his efforts pursuant to the ASU Agreement.
  
 ARTICLE III. AGREEMENT TERM. This Agreement shall be effective on the date of the last signature hereto, and terminate on September 30, 2021. Any IRP issued under this Agreement during the term shall be effective for the period set forth in the IRP even if said period extends beyond the term of this Agreement. This Agreement term may be modified or extended at any time by mutual written consent of both parties.
  
 ARTICLE IV. SPECIAL PROVISIONS.
  
 1. Compensation. Compensation for each IRP issued by Sponsor to GREENBIO hereunder shall be on a fixed price basis and specified in each IRP. Sponsor shall remit one hundred percent (100%) of the total IRP amount upon agreement by both parties on each IRP.
  
 GREENBIO reserves the right to discontinue the Services under an IRP if Sponsor fails to make payments within ten (10) days of the starting date of an IRP.
   
  
 		 Page 1

 
 
  
 
 	 
	
	

	 

 
 
  
 
 In the event of non-payment, GREENBIO may terminate all further work on an IRP and seek full payment from the Sponsor for all work performed and all expenses incurred including allocable costs, pursuant to the termination clause of this agreement including the collection of payment.
  
 Should it become necessary for GREENBIO to commence collection proceedings or retain an attorney to enforce any of the terms of this Agreement, the Sponsor shall pay attorneys’ fees and the costs of collection incurred by GREENBIO.
  
 Please send checks or paper remittance advices to: 
  
 GreenBio AZ INC
 123 Drummond Farms Ln 
 Newark, DE 19711
  
 Wire transfers should be sent to: 
  
  
  
 Questions should be directed to the person issuing the invoice or to greenbioaz.acctg@gmail.com
  
 2. Publications. Sponsor recognizes that under GREENBIO policy the results of work performed under this Agreement must be publishable and agrees that GREENBIO and its employees engaged in work under this Agreement shall be free to present at symposia or professional meetings, and to publish in journals, theses or dissertations, or otherwise of their own choosing, methods and results of the work performed under this Agreement. Upon written request by Sponsor, copies of proposed manuscripts will be furnished to Sponsor for review prior to publication. Sponsor reserves the right to request removal of any material that includes Confidential Information of Sponsor. In no event will GREENBIO delay publication for more than thirty (30) days from date of submittal of manuscript for Sponsor review.
   
  
 		 Page 2

 
 
  
 
 	 
	
	

	 

 
 
  
 
 3. Notices. All official notices, by either party, required or permitted under this Agreement will be in writing and will be given by personal delivery against receipt (including private courier such as FedEx), email with “Read Receipt” or certified U.S. Mail, return receipt requested. All notices will be sent to the addresses below or such other addresses as the parties may specify in the same manner. Notices will be deemed to have been given and received on the date of actual receipt or on the date receipt was refused. Courtesy email copy of any notice is requested to be sent to the PI. Addresses are as follows:
   
  
 	 GreenBio AZ INC 
 123 Drummond Farms Ln 
 P.O. Box 876011 
 Newark DE 19711 
 greenbioaz.acctg@gmail.com 
 (302) 763-2646 
	  
	 For Sponsor:
 William A. Hartman
 Halberd Corporation
 P.O. Box 25
 Jackson Center, PA 16133
 WillialAHartman@aol.com
 (814)-786-8849

 
 
  
 
 cc: PI email address: Shawn.q.chen@gmail.com
  
 4. Intellectual Property.
  
  
 	  
	 a)
	 Intellectual Property resulting from the performance of IRPs under this Agreement paid for by Sponsor will be owned by Sponsor (“Sponsor IP”), but subject to a 5% royalty to GREENBIO or its designees, as in the case of the ASU Master Agreement.

	  
	  
	  

	  
	 d)
	 GREENBIO and Sponsor shall separately retain ownership of all intellectual property and materials owned by such party, prior to the date hereof.

	  
	  
	  

	  
	 e)
	 “Intellectual Property” shall mean any inventions, discoveries, concepts, methods, processes, data, copyrights, computer programs and related documentation, works of authorship fixed in a medium of expression, or mask works, whether or not patentable, copyrightable or subject to mask work rights or other similar statutory rights, as well as applications for any such rights.

 
 
  
 
  
 	  
	 2) 
	 PATENT APPLICATIONS. Patent applications will be filed by GREENBIO on GREENBIO IP and Joint IP. Sponsor may, at any time, request to file a patent application on GREENBIO IP or Joint IP. In either case, the parties shall jointly participate in that process.

	  
	  
	  

	  
	 3) 
	 OPTION. In consideration of Sponsor’s support of this Project, Sponsor shall be entitled to an option to negotiate a royalty-bearing license of 5% to GREENBIO IP and/or GREENBIO’s interest in Joint IP, so long as Sponsor agrees to reimburse GREENBIO for all patent costs plus a 15% patent administration charge during the term of the option. Failure to reimburse patent costs plus a 15% patent administration charge will result in termination of this option.

 
 
  
 
  
 	  
	 a)
	 Sponsor must exercise the option in writing to GREENBIO within thirty (30) days of GREENBIO’s notification to Sponsor of any invention/discovery or within thirty (30) days of the termination of the Project, whichever occurs sooner.

 
 
  
  
  
 		 Page 3

 
 
  
 
 	 
	
	

	 

 
 
  
 
  
 	  
	 b)
	 Aside from the rate itself, the specific terms of any license must be negotiated in good faith within three (3) months of Sponsor’s written notification that it wishes to exercise the option. Said license shall contain reasonable terms that are standard in the industry for the GREENBIO IP and/or GREENBIO’s interest in Joint IP, shall require diligent performance by Sponsor for the timely commercial development and marketing of such GREENBIO IP and/or GREENBIO’s interest in Joint IP, and shall include Sponsor’s obligation to reimburse GREENBIO’s patent costs plus a 15% patent administration charge for all inventions subject to the license.

 
 
  
  
  
 	  
	4) 	 DISCLOSURE. Sponsor shall retain all invention disclosures submitted by GREENBIO in confidence and use its best efforts to prevent disclosure to third parties. Sponsor shall be relieved of this obligation only when this information becomes publicly available through no fault of Sponsor. Consistent with its duties as a public company, Sponsor will issue press releases and engage in social media.

 
 
  
  
 5. Confidentiality. The parties may, at their discretion, and in connection with work contemplated or performed under this Agreement, disclose their respective proprietary or confidential information (“Confidential Information”) to each other. To be protected hereunder, Confidential Information must be marked confidential if disclosed in written or other tangible form. If Confidential Information is disclosed orally or visually, Confidential Information must be identified as confidential at the time of disclosure and reduced to writing, marked confidential, and transmitted to the receiving party within thirty (30) days of the initial disclosure.
  
 Nothing in this Agreement will be construed to convey to either party any right, title or interest in any Confidential Information provided by the other party or any right, title or interest in any intellectual property of the parties, including but not limited to, processes, copyrights or patents. No license to the receiving party under any trademark, patent or copyright is either granted or implied by the conveying of Confidential Information to the receiving party.
  
 The receiving party will not use, or disclose to any third party, Confidential Information of the disclosing party in any manner except for the purposes of this Agreement, and will require that its employees and agents who have access to such information maintain the same in strict confidence subject to the same restrictions. By way of example, but not limitation, the receiving party will not use Confidential Information of the disclosing party in connection with any patent application, for any commercial purpose, or for the benefit of any third party.
   
  
 		 Page 4

 
 
  
 
 	 
	
	

	 

 
 
  
 
 The parties will use reasonable efforts to prevent the disclosure to unauthorized third parties of any Confidential Information of the other party and will use such information only for the purposes of this Agreement. The receiving party’s obligations with respect to Confidential Information will survive for three (3) years after the termination of this Agreement; provided that the receiving party's obligations hereunder will not apply if the receiving party can show, with convincing written evidence that the Confidential Information of the disclosing party received under this Agreement:
  
  
 	  
	 a)
	 was already known to the receiving party prior to the time of first disclosure; or

	  
	  
	  

	  
	 b)
	 at the time of disclosure is in the public domain, or after the date of the disclosure, lawfully becomes a part of the public domain other than through breach of this Agreement by the receiving party; or

	  
	  
	  

	  
	 c)
	 is received in good faith, without any obligation of confidentiality from a third party having a legal right to disclose the same; or

	  
	  
	  

	  
	 d)
	 is independently developed by the receiving party by individuals without access to such information; or

	  
	  
	  

	  
	 e)
	 is required to be disclosed by the receiving party pursuant to a legally enforceable order, law, subpoena, or other regulation (“Order”), provided, however, that the receiving party promptly notifies the disclosing party in advance of such disclosure and discloses only that Information necessary to comply with said Order.

 
 
  
 
 GREENBIO retains the right to refuse acceptance of any Confidential Information that is not required for the purposes of this Agreement.
  
 ARTICLE V. GENERAL PROVISIONS.
  
 1. Entire Agreement; Amendments; Counterparts. This Agreement embodies the entire understanding of the parties and supersedes any other agreement or understanding between the parties relating to the subject matter. The parties agree that should any part of this Agreement be held to be invalid or void, the remainder of the Agreement shall remain in full force and effect and shall be binding upon the parties. This Agreement may be executed in counterparts, each of which will be deemed an original. Electrionically transmitted and imaged copy signatures will be fully binding and effective for all purposes.
  
 2. Waivers. No waiver, amendment or modification of this Agreement shall be valid or binding unless written and signed by the parties. Waiver by either party of any breach or default of any clause of this Agreement by the other party shall not operate as a waiver of any previous or future default or breach of the same or different clause of this Agreement.
  
 3. Assignment. Neither party may transfer or assign this Agreement or any of other party’s rights or obligations hereunder, directly or indirectly, or by operation of law, without that party’s prior written consent, and any attempt to the contrary will be void.
  
 4. Governing Law and Venue. This Agreement will be governed by the laws of the State of Arizona without regard to any conflicts of laws principles. Any proceeding arising out of or relating to this Agreement will be conducted in Maricopa County, Arizona. Each party consents to such jurisdiction, and waives any objection it may have to venue or convenience of forum.
   
  
 		 Page 5

 
 
  
 
 	 
	
	

	 

 
 
  
 
 5. Independent Contractor. GREENBIO is an independent contractor and will be free to exercise its discretion and independent judgment as to the method and means of performance of its work hereunder. GREENBIO employees will not be considered employees of Sponsor, and neither GREENBIO nor Sponsor personnel will, by virtue of this Agreement, be entitled or eligible, to participate in any benefits or privileges given or extended by the other party to its employees.
  
 6. Termination. Either party may at any time terminate this Agreement by giving the other party not less than thirty (30) days prior written notice. In the event this Agreement is canceled by Sponsor, Sponsor will remain responsible for payment to GREENBIO for all work performed through the date of termination and for reimbursement to GREENBIO of all non-cancelable commitments incurred in the conduct of the research. Non-cancelable commitments will include employment commitments to GREENBIO personnel through the end of the semester following any such termination by Sponsor. In the event GREENBIO terminates this Agreement any unused funds from the reserve will be returned.
  
 7. Dispute Resolution. In the event of any dispute, claim, question, or disagreement arising from or relating to this Agreement or the breach thereof, the parties hereto will use their reasonable efforts to settle the dispute, claim, question, or disagreement. To this effect, they will consult and negotiate with each other in good faith and, recognizing their mutual interests, attempt to reach a just and equitable solution satisfactory to both parties.
  
 * * * Signature Page Follows * * *
   
  
 		 Page 6

 
 
  
 
 	 
	
	

	 

 
 
  
 
 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by its duly authorized representatives on the respective dates entered below.
  
  
 	 GREENBIO 
	  
	 Sponsor: ________________________________
	
	  
	  
	  
	  
	  
	  

	 By:
	  
	  
	 By:
	                
	  

	  
	  
	  
	  
	  
	  

	 Name:
	 Hong Hou
	  
	 Name:
	                
	  

	  
	  
	  
	  
	  
	  

	 Title:
	 President
	  
	 Title:
	                
	  

	  
	  
	  
	  
	  
	  

	 Date:
	  
	  
	 Date:
	                
	  

 
 
  
  
  
 		 Page 7

 
 
  
 
 	 
	
	

	 

 
 
  
 
 EXTENSION EXHIBIT A
 to GREENBIO Agreement No.              020821-1              
  
 Scope of Work
  
  
 	 1.
	 Producing metal-conjugated Alzheimer’s Disease related antibodies against tau, phosphorylated tau, beta amyloid, and/or other identified antigens agreed to between the parties.

	  
	  

	 2.
	 Testing the efficacy of metal-conjugated mAb in eliminating Alzheimer’s Disease associated antigens by particular radio frequency and/or laser exposure.

 
 
  
  
  
 		 Page 8

 
 
  
 
 	 
	
	

	 

 
 
  
 
 EXTENSION EXHIBIT B
 to Master Agreement No.               020821-1               
  
 Individual Research Project (IRP) No. 020821-2 
 under
 Master Agreement No.              020821-1               
 Between
 The GREENBIO
 And 
 Halberd Corporation
  
 Per the Master Agreement effective MM/DD/YYY, this IRP, as specified in IRP Scope of Work attached hereto, is hereby authorized. The terms and conditions specific to this IRP are as follows:
  
  
 	 1. 
	 Funding total $ 60,000 (does not include cost associated with purchasing radio frequency (RF) equipment), payable $30,000 prior to the June 7, 2021 commencement and $30,000 on or before July 1, 2021.

	 2.
	 Period of Performance is from 06/07/2021 through 08/31/2021

	 3.
	 Scope of work

 
 
  
 
 	  
	 a)
	 Modify and activate gold-coated iron nanoparticles

	  
	 b)
	 Conjugte monoclonal antibodies against Alzheimer’s Disease antigens

	  
	 c)
	 Characterize gold-coated iron monoclonal antibody

	  
	 d)
	 Halberd will provide the RF equipment. Setup and calibrate RF system for biological samples.

	  
	 e)
	 Test the efficacy of metallic-labelled monoclonal antibody in killing Alzheimr’s Disease antigens in solution by various radio frequencies.

	  
	 f)
	 Set up and calibrate laser for biological samples.

	  
	 g)
	 Test efficacy of metallic labelled monoclonal antibody in killing Alzheimr’s Disease antigens in solution by laser emissive energy.

 
 
  
 
 All other provisions set forth in the aforementioned Agreement shall remain the same.
  
 IN WITNESS WHEREOF, the parties have caused this IRP to be executed by their duly authorized representatives. IRP effective the date of last signature by the authorized representatives.
   
  
 		 Page 9

 
 
  
 
 	 
	
	

	 

 
 
  
  
  
 	 Halberd Corporation
	  
	 GREENBIO
	  

	  
	  
	  
	  
	  
	  

	  
	 /s/ William A. Hartman
	  
	  
	 /s/ Hong Hou
	  

	  
	  
	  
	  
	  
	  

	 NAME
	 William A. Hartman
	  
	 NAME
	 Hong Hou
	  

	  
	  
	  
	  
	  
	  

	 Title:
	 Chairman, President, CEO
	  
	 Title:
	 President
	  

	  
	  
	  
	  
	  
	  

	 Date:
	 3-Jun-21
	  
	 Date:
	 June 3, 2021
	  

 
 
  
  
  
 		 Page 10halb_ex106.htm

EXHIBIT 10.6
  
 
  
  
  
 
 	 To:
	 Dr. Mitchell Felder 

		 Halberd Corporation

	  
	 P.O. Box 25

	  
	 Jackson Center, PA 16133

	 Email:
	 mitchellf6@gmail.com

	 Phone:
	 (814) 786-8849

	 Cell Phone:
	 (724) 372-5242

	 Date:
	 May 10, 2022

	 From:
	 Alan P. Schwartz, Executive Vice President 
 mdi Consultants, Inc.

	 Tel:
	 (516) 482-9001

	 Email:
	 alan@mdiconsultants.com

	 Inquiry #:
	 15755rr1

	 RE:
	 Assistance in Regulatory Strategy, Pre-Sub Assistance, Software Validation Assistance, 510(k) or DeNovo Assistance, QSR Compliance, and Ongoing Services for Device for Treatment of Blood

 
 
  
 
 
 
 Dear Dr. Felder:
  
 As per my discussion with Randy, attached is a revised proposal for mdi to provide the following services with the goal of marketing the device in the USA:
  
  
 
 	  
	 I.
	 Assistance in Regulatory Strategy

	  
	 II.
	 Pre-Sub Assistance

	  
	 III.
	 Software Validation Assistance

	  
	 IV.
	 510(k) or DeNovo Assistance

	  
	 V.
	 QSR Compliance

	  
	 VI.
	 Ongoing Services

 
 
  
 
 
  
 Please note that we have included the fees for Parts I and II. The others will be added once we get a better handle on the project. Our team will be available to work closely with you and your team to ensure the timely success of this project. Please review the proposal and if there are any questions, do not hesitate to contact me.
  
 Regards,
  
 mdi Consultants, Inc. 
 Alan P. Schwartz 
 Executive Vice President 
 APS:sl
 Enc.
  
  
 
 	 
	1
	

	 

 
 
  
 
 
 
 mdi Consultants, Inc.
 Proposal prepared for Halberd Corporation 
 May 17, 2022
 Inq. # 15757rr1
  
 Retainer Agreement
  
 Project Scope
  
 mdi Consultants, Inc. would be able to provide Halberd Corporation, of Jackson Center, PA, the following services for ensuring full FDA compliance and getting their blood treatment to market through the FDA review process:
  
  
 
 	  
	 1.
	 Assistance in Regulatory Strategy

	  
	 2.
	 Pre-Sub Assistance

	  
	 3.
	 Software Validation Assistance

	  
	 4.
	 510(k)or DeNovo Preparation and Submission

	  
	 5.
	 Setting up Quality System Manual Compliance

	  
	 6.
	 Ongoing Services

 
 
  
 
 
  
 Services
  
 It is understood that the Client may have limited technical expertise in the above subject matter and regulatory tasks, and mdi will be responsible to provide the necessary expertise as needed to prepare and complete the foregoing submissions to the FDA.
  
 Part I: FDARegulatory Strategy
  
  
 
 	  
	 1.
	 Review the product documentation for the device provided to FDA for the initial Q- sub as well as any other device information that may be helpful in determining possible strategies. Prepare and submit Q-sub and handle FDA communications related thereto.

	  
	 2.
	 Review the Q-sub response from the FDA in-depth and provide our feedback on the reviewer comments.

	  
	 3.
	 Provide options for regulatory strategies to move forward with the FDA submission.

	  
	 4.
	 Discuss via teleconference or virtual means (e.g. Zoom) the proposed strategies, including pros and cons of each.

	  
	 5.
	 Answer any questions regarding the possible strategies to move forward.

	  
	 6.
	 mdi will provide guidance and assistance for the preparation of clinical trials. mdi will review the clinical trial protocols to make sure it meets FDA requirements prior to submission to the FDA with the pre-sub (Part II below) (mdi does not write the clinical protocols).

 
 
  
 
 
  
 Part II: Pre-Submissionto FDA (if determined necessary)
  
  
 
 	  
	 1.
	 Provide guidance to the team in required documentation for the pre-submission.

	  
	 2.
	 Review the proposed product labeling, proposed indications for use, and other relevant device information.

	  
	 3.
	 Review the clinical test protocol and supporting documents.

	  
	 4.
	 Review the testing performed on the subject device. (recommend labs for testing)

	  
	 5.
	 Work closely with the staff to compile necessary information for the pre-submission.

 
 
  
 
 
 
  
 
 	 
	2
	

	 

 
 
  
 
 
 
 mdi Consultants, Inc.
 Proposal prepared for Halberd Corporation 
 May 17, 2022
 Inq. # 15757rr1
  
  
 
 	  
	 6.
	 Review documents for completeness; compile paper and electronic applications for FDA submission.

	  
	 7.
	 Prepare the submission and after approval from the Client, submit the pre-submission to the FDA. (There are no FDA fees for the pre-submission).

	  
	 8.
	 Monitor the pre-submission through the FDA review.

	  
	 9.
	 If there are any additional requests for information, assist with the preparation of this information and submit it to the FDA.

	  
	 10.
	 Act as liaison with the FDA reviewer until pre-submission feedback has been received.

 
 
  
 
 
  
 After receipt of the FDA response, mdi will be available to outline the regulatory strategy.
  
 Timeframe: mdi will need 2-3 weeks to prepare the pre-submission once all the necessary information is provided by the Client. To the extent needed or requested by the client, mdi will be responsible to provide any expertise needed for the submission to the FDA, including guidance of clinical trial protocols, guidance on the required product testing (FDA review time is approximately 45-60 days). (FDA changed their timeframes due to the COVID work burden.)
  
 Part III: Software Validation- FDA requires that the software in the device is to be validated as part of the 510(k). This is what will be done to assist with this process:
  
  
 
 	  
	 1.
	 Review software design control documentation;

	  
	 2.
	 Review SH software development control SOPs;

	  
	 3.
	 Discuss/ Review software system hazard analysis;

	  
	 4.
	 Discuss/ Develop cybersecurity documentation;

	  
	 5.
	 Discuss/ Develop software validation test plan;

	  
	 6.
	 Software validation test protocols;

	  
	 7.
	 Review test results.

 
 
  
 
 
  
 Time schedule: 30 days with participation of Halberd team.
  
 Part IV: Market Approval (DeNovo) or 510(k) Submission to FDA
  
  
 
 	  
	 1.
	 Review the product labeling and information to determine what testing would be required by the FDA to obtain market clearance/approval.

	  
	 2.
	 Review all the clinical test data required for the market clearance/approval submission.

	  
	 3 
	 Provide a list of test data required for the market clearance/approval submission including identification of applicable ISO standards and their FDA recognized revisions for required tests.

	  
	 4.
	 Determine which process validation requirements apply to your device (if De Novo).

	  
	 5.
	 Review the software validation and documentation to ensure it is in-line with the FDA software validation guidelines.

	  
	 6.
	 If 510(k) pathway is used, review the comparison chart showing similarities and differences between the new device and the substantially equivalent device.

 
 
  
 
 
 
  
 
 	 
	3
	

	 

 
 
  
 
 
 
 mdi Consultants, Inc.
 Proposal prepared for Halberd Corporation 
 May 17, 2022
 Inq. # 15757rr1
  
  
 
 	  
	 7.
	 Prepare the appropriate application for submission to the FDA in both e-copy and hard copy format.

	  
	 8.
	 After the Client’s review and approval, submit the application to the FDA.

	  
	 9.
	 Make the appropriate user fee payments to the FDA in accordance with their guidelines (assist with the small business application to obtain a reduction of user fees if applicable).

	  
	 10.
	 Monitor the application through the FDA review process.

	  
	 11.
	 If there are any additional requests for information, assist with the preparation of this information and submit it to the FDA.

	  
	 12.
	 Act as liaison with the FDA reviewer until market approval is obtained.

 
 
  
 
 
  
 Timeframe: mdi will require 4-5 weeks to prepare the submission once all the necessary information is provided by the Client. FDA review time could be between 3-6 months. (The FDA changed their timeframes due to the COVID work burden.)
  
 Part V: Assistance with Quality System Implementation for US FDA Quality System Regulations (21CFR820 QSR/cGMP)
  
  
 
 	  
	 1.
	 Visit Halberd Corporation, operations and meet with the management team.

 
 
  
 
 
 
 
 	  
	 a.
	 Provide training to the management team on an introduction to the FDA and the FDA QSR requirements to achieve compliance for their operations.

 
 
  
 
 
 
 
 	  
	 2.
	 mdi will supply a Quality System Manual, which will be customized with the assistance of the Halberd Corporation team. This manual will include all forms necessary to maintain compliance with the necessary procedures for their operation as an initial importer and distributor.

 
 
  
 
 
 
 
 	  
	 a.
	 Halberd Corporation personnel will be responsible to prepare the work instructions.

 
 
  
 
 
 
 
 	  
	 3.
	 After Halberd Corporation has had a chance to implement the new quality system, audit the operations to determine ongoing compliance to FDA regulations.

	  
	 4.
	 Provide a written audit report documenting any observed deficiencies.

	  
	 5.
	 Provide guidance with implementing required corrective actions to address the deficiencies.

	  
	 6.
	 Be available to answer any questions related to quality system compliance.

 
 
  
 
 
  
 Project timeframe: The project will be managed by a senior consultant with extensive medical device Quality Systems experience. In cases where physical presence is not permitted or desired due to the Covid-19 outbreak, the project will be conducted via the internet and phone. We estimate 30-45 days to complete the customization of the quality system manual and review of the SOPs. Compliance to the quality system would need to be determined via a visit and mock audit.
  
  
 
 	 
	4
	

	 

 
 
  
 
 
 
 mdi Consultants, Inc.
 Proposal prepared for Halberd Corporation 
 May 17, 2022
 Inq. # 15757rr1
  
 Part VI: Ongoing Consulting Services
  
  
 
 	  
	 1.
	 Act as Official Correspondent with the FDA.

 
 
  
 
 
 
 
 	  
	 a.
	 Submit the annual registration.

	  
	 b.
	 Submit the Medical Device Listing and update it as needed.

 
 
  
 
 
 
 
 	  
	 2.
	 Assist with evaluation of complaints to determine if Medical Device Reports (MDR) are required. Assist with the preparation of MDR reports and submit via electronic filing.

	  
	 3.
	 Provide ongoing consultation on regulatory and compliance matters and policies concerning device changes and 510(k) updates.

	  
	 4.
	 Assist with 510(k) preparation and submissions (to be quoted separately).

	  
	 5.
	 Provide unlimited telephone consultation.

	  
	 6.
	 Conduct the annual internal audit in accordance with the FDA’s QSR.

	  
	 7.
	 Conduct vendor audits for compliance with the FDA’s QSR.

	  
	 8.
	 Be available for FDA inspections of your operations and facilities.

	  
	 9.
	 Assist with various correspondence pertaining to the FDA.

	  
	 10.
	 Provide FDA strategic planning for obtaining additional FDA clearances/approvals.

 
 
  
 
 
  
 Fee Schedule
  
 For the above services, Halberd Corporation would be required to pay mdi Consultants, Inc. the following:
  
 Part I: FDARegulatory Strategy
  
 mdi’s fee for this part will be $2,000.00/month for a period of six months. The fee is to be paid monthly as per the stated amount and/or up to the time, Part II goes into effect and the Pre-sub is being prepared.
  
 Part II: Pre-Submissionto FDA (if determined to be recommended)
  
 For the pre-submission services, the Client will be required to pay mdi Consultants a fee of
 $10,000.00. The fee is to be paid as follows:
  
  
 
 	  
	 ·
	$ 6,000.00 – To initiate the pre-submission process
	  
	 ·
	$ 3,000.00 – Prior to submission to FDA
	  
	 ·
	$ 1,000.00 – Upon FDA response

 
 
  
 
 
  
 Part III: Software Validation
  
 The fee for software validation assistance will be $11,500.00.
  
 Payment is due as follows: 50% to initiate the software validation project, 25% within 14 days of the commencement of the project, and 25% upon receipt of the final report.
  
  
 
 	 
	5
	

	 

 
 
  
 
 
 
 mdi Consultants, Inc.
 Proposal prepared for Halberd Corporation 
 May 17, 2022
 Inq. # 15757rr1
  
 Part IV: Market Approval (DeNovo) or 510(k) Submission to FDA
  
 After the FDA responses to our Pre-sub, we will learn if we can do a traditional 510(k) submission or would be required to submit a DeNovo application. Consulting fees will be determined after the approach is clear. User fees are additional and are explained below.
  
 The FDA user fee is $45,000.00* for the De Novo submission review or $12.432.00* for the traditional 510(k) and are in addition to the consulting fees and will need to be paid to the FDA two weeks prior to submission.
  
 *If you desire a discounted De Novo user fee for a small business in the amount of $27,474.00, for the DeNovo (or $3,186.00 for the traditional 510(k)), you will need to get the small business application to the FDA six weeks prior to the time the user fee payment is made. The small business user fee applies to companies with less than $100 million in annual revenues. mdi can provide the FDA link for the small business FDA application.
  
 For the DeNovo or the 510(k), there is a $100.00 fee to cover all administrative expenses associated with the project.
  
 The FDA official 510(k) notice will be only sent after final payment is received. All taxes are to be paid by the client.
  
 Part V: Assistance with Quality System Implementation for US FDA Quality System Regulations (21CFR 820 QSR/cGMP)
  
 The fee for these services will be determined.
  
 Part VI. Ongoing FDA Regulatory Assistance
  
 This Part (services 1-9 exclusive of 4) will be initiated after Part V has been completed. The fee will be determined at a later date.
  
 Expenses
  
 All expenses are additional and include: Airfare (selected at auditor’s discretion), travel to and from the airports, hotel, meals during travel, rental car and gas, local parking at airports for private vehicles or transportation between airport and home. While onsite in PA up to $50.00 USD will be needed for miscellaneous expenses (with receipts and does not include personal entertainment) per person, per trip. In addition, travel time is invoiced at $1,000.00/man-day and will be charged for each full day of travel for each auditor, and prorated for portions thereof. (For Part I, the travel time is included in the fees.)
  
 Additional expenses to be invoiced include costs for postage, copying, and a $25.00 service fee for each wire transfer.
  
 All lab tests are additional.
  
  
 
 	 
	6
	

	 

 
 
  
 
 
 
 mdi Consultants, Inc.
 Proposal prepared for Halberd Corporation 
 May 17, 2022
 Inq. # 15757rr1
  
 FDA annual registration fees are additional.
  
 Changes and Cancellation
  
 The parties will discuss and agree on continuation of the project in advance of each part, including the portions and actions thereof which may be thereafter cancelled including any potential penalties therefor. The project will continue (with appropriate, agreed upon compensation for expenditures in advance of work by mdi). If for any reason, the project does not proceed, mdi will be reimbursed for all costs it makes in advance, in the expectation of further work. However, there shall be no cancellation penalties occur if the Client cancels, either because the project is technically or economically unfeasible or if, in the unlikely event, the Client becomes dissatisfied with mdi’s work; provided however, without cause, client will always be obligated to pay for MDI’s work, in accordance with this Agreement.
  
 Retainer Agreement below.
  
  
 
 	 
	7
	

	 

 
 
  
 
 
 
 mdi Consultants, Inc.
 Proposal prepared for Halberd Corporation 
 May 17, 2022
 Inq. # 15757rr1
  
 Retainer Agreement
  
 We are in agreement with the terms and agreement and wish to retain mdi for the following projects (please initial desired projects):
  
  
 
 	  
	 Part I:
	☐
		 Part II:
	 ☐

		 Part III:
	 ☐ tbd

		 Part IV:
	 ☐ tbd

		 Part V:
	 ☐ tbd

		 Part VI:
	 ☐ tbd

 
 
  
 
 
 
  
 
 	 For:
	 Halberd Corporation
 P.O. Box 25
 Jackson Center, PA 16133
	  
	 For:
	 mdi Consultants, Inc. 
 55 Northern Blvd.
 Great Neck, NY 11021
	  

	  
	  
	  
	  
	  
	  

	  
	 /s/ William A. Hartman
	  
	  
	  
	  

	  
	 Signature
	  
	  
	 Signature
	  

	  
	  
	  
	  
	  
	  

	  
	 William A. Hartman, CEO
	  
	  
	 Alan Schwartz, EVP
	  

	  
	 Name and Title
	  
	  
	  
	  

	  
	  
	  
	  
	  
	  

	  
	 May 17, 2022
	  
	  
	  
	  

	  
	 Date
	  
	  
	 Date
	  

 
 
  
 
 
  
 Wiring instructions:
  
  
  
 There is an additional $25.00 for each wire.
  
 Also, if you are using another company name on the account for wiring, please notify us of the name to ensure correct crediting.
  
 If you have any questions, please contact Mrs. Diane Furnari, mdi’s office manager, (diane@mdiconsultants.com, 516-482-9001).
  
  
 
 	 
	8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00347-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00347-of-00352.parquet"}]]